By Fineline Cube 
China‑based Sino Biopharmaceutical (HKG: 1177) announced today that its internally‑developed Class 1 innovative drug LM‑2417 has successfully enrolled its first patient in a Phase I clinical trial in China. The milestone marks a critical step toward evaluating the safety and pharmacodynamics of this novel bispecific antibody in patients with advanced solid tumours.
What Is LM‑2417?
LM‑2417 is a NaPi2b/4‑1BB bispecific antibody engineered by LaNova Medicine on a proprietary conditionally‑activated 4‑1BB platform. The dual‑specificity design allows the antibody to simultaneously bind the tumour‑specific NaPi2b antigen and the immune‑cell co‑stimulatory receptor 4‑1BB. By localising immune activation to the tumour microenvironment, LM‑2417 aims to amplify antitumour immunity while limiting systemic toxicity.
Phase I Trial Design
The first‑in‑human study will enroll patients with refractory or metastatic solid tumours that express NaPi2b. Participants will receive escalating doses of LM‑2417 to determine the maximum tolerated dose, dose‑limiting toxicities, and pharmacokinetic profile. The trial will also collect tumour biopsies and peripheral blood samples to assess immune activation markers and early efficacy signals.
Strategic Significance
- Innovation Leadership – Sino Biopharmaceutical’s entry into bispecific antibody development positions it among the few Chinese companies pursuing advanced immuno‑oncology platforms.
- Collaborative Edge – The partnership with LaNova Medicine leverages complementary expertise in antibody engineering and clinical oncology, potentially accelerating regulatory approval.
- Market Opportunity – With the global bispecific antibody market projected to exceed $10 billion by 2035, early clinical data for LM‑2417 could unlock significant commercial upside.-Fineline Info & Tech